Grant S. Schulert

Grant S. Schulert

Auto-generated profile, based on publicly available information

Grant S. Schulert

Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
LHLauren A. Henderson
Lauren A. Henderson
SCScott W. Canna
Scott W. Canna
GSGrant S. Schulert
Grant S. Schulert
SVStefano Volpi
Stefano Volpi
PLPui Y. Lee
Pui Y. Lee
PNPeter A. Nigrovic
Peter A. Nigrovic

14 January 2015 in Annual Review of Medicine
Verified
Journal Article
Closed access
GSGrant S. Schulert
Grant S. Schulert
AGAlexei A. Grom
Alexei A. Grom
Macrophage activation syndrome (MAS) is an acute episode of overwhelming inflammation characterized by activation and expansion of T lymphocytes and hemophagocytic macrophages. In rheumatology, it occurs most frequently in patients with systemic juvenile idiopathic arthritis (SJIA) and systemic lupus erythematosus. The main clinical manifestations include cytopenias, liver dysfunction, coagulopathy resembling disseminated intravascular coagulation, and extreme hyperferritinemia. Clinically and pathologically, MAS bears strong similarity to hemophagocytic lymphohistiocytosis (HLH), and some authors prefer the term secondary HLH to describe it. Central to its pathogenesis is a cytokine storm, with markedly increased levels of numerous proinflammatory cytokines including IL-1, IL-6, IL-18, TNFα, and IFNγ. Although there is evidence that IFNγ may play a central role in the pathogenesis of MAS, the role of other cytokines is still not clear. There are several reports of SJIA-associated MAS dramatically benefiting from anakinra, a recombinant IL-1 receptor antagonist, but the utility of other biologics in MAS is not clear. The mainstay of treatment remains corticosteroids; other medications, including cyclosporine, are used in patients who fail to respond.

15 February 2021 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
LHLauren A. Henderson
Lauren A. Henderson
SCScott W. Canna
Scott W. Canna
KFKevin G. Friedman
Kevin G. Friedman
MGMark Gorelik
Mark Gorelik
SLSivia K. Lapidus
Sivia K. Lapidus
JMJay J. Mehta
Jay J. Mehta

23 July 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
LHLauren A. Henderson
Lauren A. Henderson
SCScott W. Canna
Scott W. Canna
KFKevin G. Friedman
Kevin G. Friedman
MGMark Gorelik
Mark Gorelik
SLSivia K. Lapidus
Sivia K. Lapidus
JMJay J. Mehta
Jay J. Mehta

3 February 2022 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
LHLauren A. Henderson
Lauren A. Henderson
SCScott W. Canna
Scott W. Canna
KFKevin G. Friedman
Kevin G. Friedman
MGMark Gorelik
Mark Gorelik
SLSivia K. Lapidus
Sivia K. Lapidus
JMJay J. Mehta
Jay J. Mehta
Objective: To provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS‐C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of SARS–CoV‐2 infection. Recommendations are also provided for children with hyperinflammation during COVID‐19, the acute, infectious phase of SARS–CoV‐2 infection.Methods: The Task Force is composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS‐C and hyperinflammation in COVID‐19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved anonymous voting and webinar discussion. A 9‐point scale was used to determine the appropriateness of each statement (median scores of 1–3 for inappropriate, 4–6 for uncertain, and 7–9 for appropriate). Consensus was rated as low, moderate, or high based on dispersion of the votes. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, which were prespecified before voting.Results: The guidance was approved in June 2020 and updated in November 2020 and October 2021, and consists of 41 final guidance statements accompanied by flow diagrams depicting the diagnostic pathway for MIS‐C and recommendations for initial immunomodulatory treatment of MIS‐C.Conclusion: Our understanding of SARS–CoV‐2–related syndromes in the pediatric population continues to evolve. This guidance document reflects currently available evidence coupled with expert opinion, and will be revised as further evidence becomes available.

24 February 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AJAdriana A. de Jesus
Adriana A. de Jesus
YHYangfeng Hou
Yangfeng Hou
SBStephen Brooks
Stephen Brooks
LMLouise Malle
Louise Malle
ABAngelique Biancotto
Angelique Biancotto
RGRaphaela Goldbach-Mansky
Raphaela Goldbach-Mansky
BACKGROUND. Undifferentiated systemic autoinflammatory diseases (USAIDs) present diagnostic and therapeutic challenges. Chronic interferon (IFN) signaling and cytokine dysregulation may identify diseases with available targeted treatments. METHODS. Sixty-six consecutively referred USAID patients underwent underwent screening for the presence of an interferon signature using a standardized type-I IFN-response-gene score (IRG-S), cytokine profiling, and genetic evaluation by next-generation sequencing. RESULTS. Thirty-six USAID patients (55%) had elevated IRG-S. Neutrophilic panniculitis (40% vs. 0%), basal ganglia calcifications (46% vs. 0%), interstitial lung disease (47% vs. 5%), and myositis (60% vs. 10%) were more prevalent in patients with elevated IRG-S. Moderate IRG-S elevation and highly elevated serum IL-18 distinguished 8 patients with pulmonary alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS). Among patients with panniculitis and progressive cytopenias, 2 patients were compound heterozygous for potentially novel LRBA mutations, 4 patients harbored potentially novel splice variants in IKBKG (which encodes NF-κB essential modulator [NEMO]), and 6 patients had de novo frameshift mutations in SAMD9L. Of additional 12 patients with elevated IRG-S and CANDLE-, SAVI- or Aicardi-Goutières syndrome–like (AGS-like) phenotypes, 5 patients carried mutations in either SAMHD1, TREX1, PSMB8, or PSMG2. Two patients had anti-MDA5 autoantibody–positive juvenile dermatomyositis, and 7 could not be classified. Patients with LRBA, IKBKG, and SAMD9L mutations showed a pattern of IRG elevation that suggests prominent NF-κB activation different from the canonical interferonopathies CANDLE, SAVI, and AGS. CONCLUSIONS. In patients with elevated IRG-S, we identified characteristic clinical features and 3 additional autoinflammatory diseases: IL-18–mediated PAP and recurrent MAS (IL-18PAP-MAS), NEMO deleted exon 5–autoinflammatory syndrome (NEMO-NDAS), and SAMD9L-associated autoinflammatory disease (SAMD9L-SAAD). The IRG-S expands the diagnostic armamentarium in evaluating USAIDs and points to different pathways regulating IRG expression. TRIAL REGISTRATION. ClinicalTrials.gov NCT02974595. FUNDING. The Intramural Research Program of the NIH, NIAID, NIAMS, and the Clinical Center.